PFIZER INC Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount
PFIZER INC (PFE) had Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount of $225.00 million as of 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Investments › Debt and Equity Securities
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueUpwardPriceAdjustmentCumulativeAmount · last filed 2026-08-04
- 2026-06-28: Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount $225.00M.
- 2026-03-29: Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount $225.00M.
- 2025-12-31: Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount $225.00M.
- 2025-09-28: Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount $239.00M.
| Period end | Equity Securities without Readily Determinable Fair Value, Upward Price Adjustment, Cumulative Amount |
|---|---|
| 2026-06-28 | $225.00M 10-Q · filed 2026-08-04 |
| 2026-03-29 | $225.00M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $225.00M 10-K · filed 2026-02-26 |
| 2025-09-28 | $239.00M 10-Q · filed 2025-11-04 |
| 2025-06-29 | $239.00M 10-Q · filed 2025-08-05 |
| 2025-03-30 | $223.00M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $222.00M 10-K · filed 2025-02-27 |
| 2024-09-29 | $198.00M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $214.00M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $212.00M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $213.00M 10-K · filed 2024-02-22 |
| 2023-10-01 | $213.00M 10-Q · filed 2023-11-08 |
| 2023-07-02 | $200.00M 10-Q · filed 2023-08-09 |
| 2023-04-02 | $203.00M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $203.00M 10-K · filed 2023-02-23 |
| 2022-10-02 | $201.00M 10-Q · filed 2022-11-09 |
| 2022-07-03 | $194.00M 10-Q · filed 2022-08-10 |
| 2022-04-03 | $167.00M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $156.00M 10-K · filed 2022-02-24 |
| 2021-10-03 | $151.00M 10-Q · filed 2021-11-12 |
| 2021-07-04 | $98.00M 10-Q · filed 2021-08-12 |
| 2021-04-04 | $61.00M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $61.00M 10-K · filed 2021-02-25 |
| 2020-09-27 | $63.00M 10-Q · filed 2020-11-05 |
| 2020-06-28 | $66.00M 10-Q · filed 2020-08-06 |
| 2020-03-29 | $60.00M 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |